Attovia (ATTO) Director Colin Walsh Buys $8.5M Stock

What Happened
Colin Walsh, a director of Attovia Therapeutics (ATTO), reported a series of transactions around the company's Aug 6, 2026 IPO. The most notable transaction: an open‑market purchase of 500,000 shares on Aug 6 at $17.00 per share for $8,500,000. The filing also shows an Aug 5 purchase of 85,000 shares at $21.00 ($1,785,000) plus several derivative‑related purchases on Aug 5 (~$2.25M total). On Aug 5 the filing reports dispositions (sales) totaling about 105,807 shares for roughly $2.25M. In addition, large numbers of shares were recorded as converted in connection with the IPO (preferred stock automatically converted to common stock per the filing).

Key Details

• Transaction dates: Aug 5–6, 2026. Key prices: $17.00 (500,000 shares), $21.00 (85,000 shares), multiple sales at ~$20.84–$22.19 on Aug 5.
• Cash purchase totals called out: $8.5M (500k @ $17.00) and $1.785M (85k @ $21.00). Derivative purchases on Aug 5 total ≈ $2.25M. Reported cash sales on Aug 5 ≈ $2.25M.
• Large automatic conversions: the filing records conversion of Series B and C preferred stock into common upon the IPO (conversion ratio 9.29‑for‑1 per footnote). Several large derivative‑conversion line items are shown at $0 consideration (reflecting conversion/rollover adjustments).
• Shares owned after transaction: not specified in the information you provided.
• Notable footnotes: (F1) reporting person disclaims beneficial ownership except to extent of pecuniary interest; (F2–F3) many transactions were effected by Goldman Sachs & Co. LLC (GS&Co) acting as a market maker and equity‑swap positions were originally omitted and are now included; (F5) preferred automatically converted to common on IPO; (F6–F8) clarify GS group and affiliated fund holdings.
• Filing status: This is an amended Form 4 filed Aug 28, 2026 correcting earlier omissions (including equity‑swap positions and conversion counts).

Context

• The large Aug 6 purchase (500,000 shares for $8.5M) is a direct buy and is typically more informative than routine sales, but the filing includes market‑making and GS group activity and a disclaimer of beneficial ownership, so not all reported trades necessarily reflect personal investment decisions.
• The automatic conversion of preferred to common at IPO is an administrative corporate action (9.29‑for‑1) and appears as zero‑value conversions in the filing — these reflect conversion mechanics, not cash trades.
• Equity‑swap positions and market‑maker sales were noted in footnotes; the filing states profits potentially recoverable under Section 16(b) (if any) will be remitted to the issuer.

If you want, I can estimate net share changes implied by these lines or extract totals per transaction type (cash purchases, cash sales, conversions).